Fundz

Fundz Deep Dive

Everything you need to win Kim-Hien Dao — in one platform.

Who to reach, what to say, and why now on Kim-Hien Dao — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Kim-Hien Dao — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

Electra Therapeutics Appoints Graham Parry As Chief Scientific Officer and Kim Hien Dao As Chief Medical Officer

PRIVATEJun 03, 2024•about 2 years ago

Position

Chief Medical Officer

Company

Electra Therapeutics

Kim-Hien Dao
San FranciscoBiotechnology

Description

Electra Therapeutics, Inc. announced the appointment of Graham Parry, PhD, as Chief Scientific Officer and Kim-Hien Dao, DO, PhD, as Chief Medical Officer. Both executives have deep experience in drug development and each have been instrumental in leading multiple drug candidates through clinical trials and toward regulatory approval.

Company Information

Company

Electra Therapeutics

Location

San Francisco, California, United States

About

Electra Therapeutics is a clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Electra Therapeutics's next move

Learn about Strategic plan

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.